Peptide mapping is an identity-confirmation method: a peptide or protein is broken into smaller fragments in a controlled way, and those fragments are separated and measured to produce a characteristic pattern - a map - that should match the expected sequence. Where a purity number tells you how much of a sample is one clean peak, a peptide map speaks to a different question entirely: is this actually the molecule the label claims? For research-use-only materials, understanding this method helps you read a certificate of analysis (CoA) as evidence rather than as marketing.
What does peptide mapping actually mean?
Peptide mapping describes any workflow that fragments a molecule and then analyses the resulting pieces to confirm identity. For larger peptides and proteins, an enzyme (such as a protease) cleaves the chain at predictable points, producing a reproducible set of fragments. Those fragments are separated - typically by HPLC (high-performance liquid chromatography) - and often measured by mass spectrometry to read each fragment mass. The resulting pattern is compared against what the known sequence should produce. If the observed map matches the theoretical map, that is strong evidence the sample is the claimed compound and not a look-alike. The term overlaps with fragment analysis more broadly, including tandem mass spectrometry (MS/MS), where a molecule is fragmented inside the instrument. In every case the logic is the same: a matching fingerprint of parts is harder to fake than a single number.
How is peptide mapping different from a purity percentage?
A purity figure answers how much; a peptide map answers what. On a CoA, purity is usually reported as a percentage by peak area from an HPLC run - the target peak as a fraction of total peak area, for example 99.0%. That number tells you the sample is mostly one substance, but it does not tell you which substance. A sample can be 99% pure and still be the wrong molecule, or the right molecule with an incorrect sequence. Peptide mapping and other fragment methods exist precisely to close that gap. As we explain in our guide on purity versus identity methods, these are two separate questions that require separate evidence. Reading a CoA well means never letting a strong purity number stand in for identity confirmation - identity and purity answer different questions, and a transparent CoA addresses both.
How does peptide mapping complement HPLC and mass spec?
The three methods form a layered picture rather than competing with one another. HPLC establishes how cleanly a sample separates into peaks. Mass spectrometry (MS or LC-MS) confirms the intact molecular mass, verifying the compound is the peptide claimed rather than one clean but unidentified substance. Peptide mapping adds a further layer: by fragmenting the molecule and confirming the masses and pattern of the pieces, it provides sequence-level evidence that the whole and its parts are consistent. Each method covers a blind spot in the others.
| Method | Primary question | Key evidence |
|---|---|---|
| HPLC | How pure? (how much of one peak) | The chromatogram |
| Mass spectrometry | What is it? (intact mass) | The mass spectrum |
| Peptide mapping | Is the sequence consistent? | The fragment pattern |
A CoA that shows all three, with the underlying traces, gives you far more to verify than any single figure.
What would a transparent CoA with peptide mapping include?
Transparency is a documentary property, not a marketing claim. A credible identity-confirmation entry on a CoA lets you check the work rather than trust the conclusion. When peptide mapping or fragment analysis is claimed, look for the following:
- The actual data trace - a chromatogram or spectrum - not just the word confirmed. A result is only as good as the evidence behind it: a chromatogram, not just a number.
- A named, independent laboratory that can be found to exist, rather than an unnamed US lab. Independent third-party labs such as Janoshik or MZ Biolabs are examples of named sources.
- A batch or lot number that matches the number printed on the vial, plus a date of analysis, since results describe a batch at a point in time.
- A verification mechanism - a code or QR that resolves on the lab's own domain, not a PDF hosted only by the vendor.
Our guide to the anatomy of a CoA walks through each of these fields in detail.
What are the red flags when identity is claimed but not shown?
Identity claims are easy to assert and harder to document, so the gaps tell you a lot. Treat the following as signals to look closer:
- The word identity confirmed or MS verified with no spectrum, chromatogram, or fragment data attached.
- A single generic certificate reused across every product, with no batch number tying it to your vial.
- A lab name that cannot be found to exist, or no lab name at all.
- A verification code, QR, or portal that leads nowhere, or a document available only by email on request after purchase.
None of these prove a sample is wrong. They mean the identity claim is not verifiable at the source, which is the property the PeptideTrust scorecard measures. An accredited testing laboratory - one meeting ISO/IEC 17025, the standard for testing-laboratory competence - is a stronger signal than an unaccredited one, but only when its report is actually shown.
Where does peptide mapping fit for short research peptides?
Context matters. Classical enzymatic peptide mapping was developed for larger proteins, where cleaving the chain into many fragments produces a rich fingerprint. Many research peptides are short, so a full digestion map may add little beyond what intact-mass MS and MS/MS fragmentation already establish. For these, direct mass measurement and tandem fragmentation are often the practical identity evidence, and their absence is more telling than the absence of a formal map. It is also worth noting that a standard purity and identity CoA usually does not include sterility or endotoxin data; those are separate tests (compendial chapters USP <71> and USP <85>, the latter measured by the LAL assay), and their absence must never be read as a sterility guarantee. A CoA describes composition, not safety, and these materials are for research use only.
How does this feed into a transparency score?
Every method above matters only insofar as its evidence is published and checkable. The PeptideTrust scoreboard does not judge whether a given peptide is good or bad; it rates vendors purely on documentary transparency - whether they publish batch-level CoAs from named, independent labs that resolve at the source. Identity confirmation, whether by peptide mapping, MS, or fragment analysis, contributes to that picture when the underlying trace, the lab name, the batch number, and a working verification path are all present. You can see exactly how those elements are weighted in our scoring methodology, which turns this literacy into ten weighted criteria. Reading a CoA is a skill: once you know what a peptide map is meant to show and what a transparent report includes, you can judge a vendor's evidence for yourself rather than taking any single number on faith.